• Salona Global Medical Device Corporation (SGMD) has announced a bought-deal private placement for gross proceeds of $4,004,000
  • The company will issue 7,280,000 units at a price of $0.55 per unit
  • Salona has also provided the underwriters with an over-allotment option for additional gross proceeds of up to $600,600
  • The offering is expected to close on or about February 15, 2022
  • Salona Global Medical Device Corp is a U.S.-based medical device company
  • Salona Global Medical Device Corporation (SGMD) opened trading at C$0.55 per share

Salona Global Medical Device Corporation (SGMD) has announced a bought-deal private placement for gross proceeds of $4,004,000.

The company will issue 7,280,000 units at a price of $0.55 per unit. Each unit will consist of one common share and one share purchase warrant. Each warrant can be exercised for one additional share at a price of $0.70 for up to three years following the closing of the offering.

Salona has also provided the underwriters with the option to purchase up to an additional 1,092,000 units, for additional gross proceeds of up to $600,600.

Net proceeds will be used for working capital and general corporate purposes.

The offering is expected to close on or about February 15, 2022.

Salona Global Medical Device Corp is a U.S.-based medical device company. 

Salona Global Medical Device Corporation (SGMD) opened trading at C$0.55 per share.

More From The Market Online

MindBio debuts AI speech tool to spot substance abuse

MindBio Therapeutics (CSE:MBIO) develops the world's first AI prediction tool for drug and alcohol intoxication using voice analysis.

An immunotherapy value play advancing the fight against bladder cancer

An in-depth look at BioVaxys Technology (CSE:BIOV), a micro-cap stock combining a promising drug pipeline with irrational investor pessimism.
The Market Online Video

Developing a neurosciences platform with potential applications across several indications

In this Capital Compass episode, Marvel Biosciences outlines progress on MB-204, its neuroscience platform targeting autism, Rett syndrome, Fragile X, and Alzheimer’s disease ahead…